Analyst Lyanne Harrison of Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), retaining the price target of ...

Aaron Wealth Advisors LLC lifted its holdings in shares of ResMed Inc. (NYSE:RMD – Free Report) by 25.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional ...

Ritholtz Wealth Management lessened its holdings in shares of ResMed Inc. (NYSE:RMD – Free Report) by 79.7% in the fourth ...

Trump's team has reportedly prepared over 100 executive orders that have far reaching consequences for the economy and ...

The day that many thought would never come has dawned: the big orange one now presides over the red button as Commander in ...

Club Med, the renowned luxury all-inclusive resort operator, has appointed independent creative agency Hopeful Monsters as ...

Hopeful Monsters wins creative for Club Med. We can't wait to see the envy-inducing work featuring cocktails by the pool.

Three Australian fund managers who delivered annualised double-digit returns over the past 10 years share their views on what ...

Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.